Cobenfy is an oral prescription medication used to treat adults with schizophrenia, combining the drugs xanomeline and trospium chloride.
It is an antipsychotic approved to treat schizophrenia that works by targeting cholinergic receptors rather than dopamine receptors, which has been the traditional standard.
Cobenfy is an oral combination drug containing xanomeline, a muscarinic receptor agonist, and trospium chloride, a muscarinic antagonist, approved for the treatment of schizophrenia in adults.
Cobenfy represents a mechanistically novel, nondopaminergic approach to schizophrenia treatment, targeting central muscarinic M1 and M4 receptors rather than dopamine D2 receptors.
Xanomeline is thought to exert its antipsychotic effect primarily through agonist activity at central M1 and M4 muscarinic acetylcholine receptors, while trospium chloride antagonizes peripheral muscarinic receptors to mitigate cholinergic side effects.
Common side effects include nausea, dyspepsia, and constipation.
It is a combination of two medications, xanomeline and trospium chloride, available in a single oral capsule.
It is not known to be safe or effective in children.
Clinical trials have shown Cobenfy to be effective in treating both positive and negative symptoms of schizophrenia.
Cobenfy has demonstrated efficacy comparable to other atypical antipsychotics, and it has shown a favorable safety profile with fewer
Cobenfy is thought to work by activating muscarinic acetylcholine receptors (specifically M1 and M4) in the brain.
Trospium chloride is included to block muscarinic receptors outside the brain, which helps minimize side effects in other parts of the body, particularly the gastrointestinal tract.
It is taken as an oral capsule twice daily on an empty stomach , at least one hour before or two hours after a meal.
Common Side Effects The most common side effects include: Nausea and vomiting Constipation and diarrhea Stomach upset or abdominal pain High blood pressure (hypertension) Increased heart rate (tachycardia) Dizziness
Patients should be monitored for potential central nervous system effects (e.g., confusion, hallucinations) and changes in heart rate.
The recommended starting dosage is 50 mg xanomeline/20 mg trospium twice daily for at least two days, then increased to 100 mg/20 mg twice daily for at least five days.
The dose may be further increased to a maximum of 125 mg/30 mg twice daily based on tolerability and response.
For geriatric patients, the maximum recommended dose is 100 mg/20 mg twice daily. Capsules should be taken at least 1 hour before or 2 hours after a meal and should not be opened.
Cobenfy does not prolong the QT interval to a clinically relevant extent.
Building on the pharmacological profile and dosing information, recent clinical trials and mechanistic studies further clarify the therapeutic role and unique attributes of Cobenfy (xanomeline/trospium) in schizophrenia.
it offers potential benefits for patients who are resistant or intolerant to traditional antipsychotics, which are associated with substantial side effects such as extrapyramidal symptoms, metabolic disturbances, and hyperprolactinemia.
Xanomeline’s central muscarinic agonism is thought to reduce dopamine release in the associative striatum, thereby improving positive, negative, and cognitive symptoms of schizophrenia, while sparing sensorimotor regions and minimizing movement and endocrine side effects.
Trospium, is a peripherally restricted muscarinic antagonist, is co-formulated to mitigate xanomeline’s cholinergic adverse events—primarily gastrointestinal—without crossing the blood-brain barrier or interfering with central efficacy.
Cobenfy significantly reduced Positive and Negative Syndrome Scale (PANSS) scores compared to placebo, with a favorable safety profile and lower rates of treatment discontinuation due to adverse events.
The combination is contraindicated in patients with moderate to severe hepatic or renal impairment or urinary retention due to the pharmacokinetics of both components.
There is potential cognitive benefits in schizophrenia and Alzheimer’s disease, and ongoing research is exploring its utility in bipolar disorder and other neuropsychiatric conditions.